GlassScriptPhysician profile
Mark H Richter
NPI 1659456523
$10,484.58
in general payments reported to CMS, 2019-2025
36 companies · $23.09 in 2025
The $23.09 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,989 · 2020: $1,984 · 2021: $2,552 · 2022: $1,844 · 2023: $1,638 · 2024: $455 · 2025: $23.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,163.79 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $975.61 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $950.96 | 2019-2022 | |
| Abbvie INC. | $863.16 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $860.82 | 2019-2024 | Jardiance |
| Pfizer INC. | $817.72 | 2019-2024 | |
| Lilly USA, LLC | $685.09 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $597.28 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $581.72 | 2019-2023 | Verquvo, Steglatro |
| Amarin Pharma, INC. | $527.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $505.92 | 2019-2023 | |
| Allergan, INC. | $229.69 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.89 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $185.76 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $137.68 | 2019-2024 | Austedo Xr |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $131.39 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.62 | 2022-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $101.08 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $99.58 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $97.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $92.28 | 2019-2022 | |
| Amgen INC. | $80.34 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $59.80 | 2019-2022 | |
| Exact Sciences Corporation | $54.66 | 2023 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $54.36 | 2022 | |
| Abbott Laboratories | $44.14 | 2021-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $42.79 | 2023-2024 | Auvelity |
| Kaleo, INC. | $41.67 | 2023 | Auvi-Q |
| Piramal Critical Care | $31.46 | 2023 | |
| Eisai INC. | $31.08 | 2020 | |
| Inari Medical, INC. | $24.11 | 2022 | |
| Scilex Pharmaceuticals INC. | $22.14 | 2019 | |
| Genentech USA, INC. | $19.13 | 2022 | |
| Circassia INC. | $16.52 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.39 | 2024 | Voquezna |
| Dermira, INC. | $13.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Richter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.